Freenome, Inc. - Common stock (FRNM)

Freenome (NASDAQ:FRNM) reported third-quarter revenue of $183.5 million, driven largely by revenue recognition following the U.S. Food and Drug Administration’s approval of its blood-based colorectal cancer screening test. The company said it does not expect meaningful testing revenue or royalties i

Ark Invest added to three existing positions on Monday, all of them down sharply from recent highs.